Background: The neutrophil/lymphocyte ratio (NLR) has been reported to reflect systemic inflammation and independent prognostic significance in different type s of cancer. In present study, we analyzed the association between NLR and clinicopathologic features and verified the significance of NLR as a prognostic factor for patients with breast cancer. Patients and Methods: A total of 388 patients with stage I - III breast cancer were retrospectively recruited into this study. Associations with clinicopathologic factors and NLR were assessed; disease-free survival and overall survival were estimated. Results: There was no significant association between NLR and clinicopathologic factors. Patients with low pre/post-treatment NLR had longer OS . Conclusion: A high pre/postoperative NLR may be considered an important factor for predicting poor prognosis in non-metastatic breast cancer patients.
KeywordsBreast CancerNLRDFSOS
Chalasani, P. (2018) Breast Cancer.
Maishman, T., Cutress, R.I., Hernandez, A., et al. (2017) Local Recurrence and Breast Oncological Surgery in Young Women with Breast Cancer: The POSH Observational Cohort Study. Annals of Surgery, 266, 165-172. https://doi.org/10.1097/SLA.0000000000001930
Hadad, S.M., Jordan, L.B., Roy, P.G., et al. (2016) A Prospective Comparison of ER, PR Ki67 and Gene Expression in Paired Sequential Core Biopsies of Primary, Untreated Breast Cancer. BMC Cancer, 16, 745. https://doi.org/10.1186/s12885-016-2788-x
Engstrøm, M.J., Opdahl, S., Hagen, A.I., et al. (2013) Molecular Subtypes, Histopathological Grade and Survival in a Historic Cohort of Breast Cancer Patients. Breast Cancer Research and Treatment, 140, 463-473. https://doi.org/10.1007/s10549-013-2647-2
Stromnes, I.M., Greenberg, P.D. and Hingorani, S.R. (2014) Molecular Pathways: Myeloid Complicity in Cancer. Clinical Cancer Research, 20, 5157-5170. https://doi.org/10.1158/1078-0432.CCR-13-0866
Ji, H., Xuan, Q., Yan, C., et al. (2016) The Prognostic and Predictive Value of the Lymphocyte to Monocyte Ratio in Luminal-Type Breast Cancer Patients Treated with CEF Chemotherapy. Oncotarget, 7, 34881-34889. https://doi.org/10.18632/oncotarget.8993
Diakos, C.I., Charles, K.A., McMillan, D.C., et al. (2014) Cancer-Related Inflammation and Treatment Effectiveness. The Lancet Oncology, 15, e493-e503. https://doi.org/10.1016/S1470-2045(14)70263-3
Motomura, T., Shirabe, K., Mano, Y., et al. (2013) Neutrophil-Lymphocyte Ratio Reflects Hepatocellular Carcinoma Recurrence after Liver Transplantation via Inflammatory Microenvironment. Journal of Hepatology, 58, 58-64. https://doi.org/10.1016/j.jhep.2012.08.017
Jiang, L., Zhao, Z., Jiang, S., et al. (2015) Immunological Markers Predict the Prognosis of Patients with Squamous Non-Small Cell Lung Cancer. Immunologic Research, 62, 316-324. https://doi.org/10.1007/s12026-015-8662-0
Cihan, Y.B., Arslan, A., Cetindag, M.F., et al. (2014) Lack of Prognostic Value of Blood Parameters in Patients Receiving Adjuvant Radiotherapy for Breast Cancer. Asian Pacific Journal of Cancer Prevention, 15, 4225-4231. https://doi.org/10.7314/APJCP.2014.15.10.4225
De Giorgi, U., Mego, M., Scarpi, E., et al. (2012) Relationship between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clinical Breast Cancer, 12, 264-269. https://doi.org/10.1016/j.clbc.2012.04.004
Chen, Y., Chen, K., Xiao, X., et al. (2016) Pretreatment Neutrophil-to-Lymphocyte Ratio Is Correlated with Response to Neoadjuvant Chemotherapy as an Independent Prognostic Indicator in Breast Cancer Patients: A Retrospective Study. BMC Cancer, 16, 320. https://doi.org/10.1186/s12885-016-2352-8
American Joint Committee on Cancer Breast, Amin, M.B., Edge, S., Greene, F., Byrd, D.R., Brookland, R.K., et al. (2017) AJCC Cancer Staging Manual. 8th Edition, Springer, New York.
Miller, K.D., Siegel, R.L., Lin, C.C., et al. (2016) Cancer Treatment and Survivorship Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 271-289. https://doi.org/10.3322/caac.21349
Tomita, M., Shimizu, T., Ayabe, T., et al. (2012) Elevated Preoperative Inflammatory Markers Based on Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein Predict Poor Survival in Resected Non-Small Cell Lung Cancer. Anticancer Research, 32, 3535-3538. https://doi.org/10.1155/2012/463520
Hwang, G.Y., Baek, D.W., Cho, H.J., et al. (2018) Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy. Anticancer Research, 38, 3151-3156. https://doi.org/10.21873/anticanres.12578
Mallappa, S., Sinha, A., Gupta, S., et al. (2013) Preoperative Neutrophil to Lymphocyte Ratio >5 Is a Prognostic Factor for Recurrent Colorectal Cancer. Colorectal Disease, 15, 323-328. https://doi.org/10.1111/codi.12008
Bhatti, I., Peacock, O., Lloyd, G., et al. (2010) Preoperative Hematologic Markers as Independent Predictors of Prognosis in Resected Pancreatic Ductal Adenocarcinoma: Neutrophil-Lymphocyte versus Platelet-Lymphocyte Ratio. The American Journal of Surgery, 200, 197-203. https://doi.org/10.1016/j.amjsurg.2009.08.041
Chen, S., Zhang, L., Yan, G., et al. (2017) Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis. BioMed Research International, 2017, Article ID: 7943467. https://doi.org/10.1155/2017/7943467
Wang, J., Zhou, X., Liu, Y., et al. (2017) Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma: A Meta-Analysis. PLoS ONE, 12, e0176008. https://doi.org/10.1371/journal.pone.0176008
Ethier, J.L., Desautels, D., Templeton, A., et al. (2017) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Breast Cancer: A Systematic Review and Meta-Analysis. Breast Cancer Research, 19, 2. https://doi.org/10.1186/s13058-016-0794-1
Ren, K., Yin, Y., He, F., et al. (2018) Prognostic Role of Derived Neutrophil-to-Lymphocyte Ratio in Surgical Triple-Negative Breast Cancer. Cancer Management and Research, 10, 4891-4898. https://doi.org/10.2147/CMAR.S180695
Das, C. (2017) Prognostic Significance of Derived Neutrophil-Lymphocyte Ratio in Non-Metastatic Breast Cancer. Advances in Human Biology, 7, 54-60. https://doi.org/10.4103/2321-8568.205387
Guthrie, G.J., Charles, K.A., Roxburgh, C.S., et al. (2013) The Systemic Inflammation-Based Neutrophil-Lymphocyte Ratio: Experience in Patients with Cancer. Critical Reviews in Oncology/Hematology, 88, 218-230. https://doi.org/10.1016/j.critrevonc.2013.03.010
Ulas, A., Avci, N., Kos, T., et al. (2015) Are Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio Associated with Prognosis in Patients with HER2-Positive Early Breast Cancer Receiving Adjuvant Trastuzumab? Journal of Buon, 20, 714-722.
Chowdhary, M., Switchenko, J.M., Press, R.H., et al. (2018) Post-Treatment Neutrophil-to-Lymphocyte Ratio Predicts for Overall Survival in Brain Metastases Treated with Stereotactic Radiosurgery. Journal of Neuro-Oncology, 139, 689-697. https://doi.org/10.1007/s11060-018-2914-5
Azab, B., Shah, N., Radbel, J., et al. (2013) Pretreatment Neutrophil/Lymphocyte Ratio Is Superior to Platelet/Lymphocyte Ratio as a Predictor of Long-Term Mortality in Breast Cancer Patients. Medical Oncology, 30, 432. https://doi.org/10.1007/s12032-012-0432-4
Elyasinia, F., Keramati, M.R., Ahmadi, F., et al. (2017) Neutrophil-Lymphocyte Ratio in Different Stages of Breast Cancer. Acta Medica Iranica, 55, 228-232.